

Special Issue

Mechanisms of Therapeutic Resistance in Glioblastoma

Message from the Guest Editors

Glioblastoma is an aggressive brain cancer with a dismal prognosis. Single-cell sequencing approaches in the past decade have revealed the transcriptomic and epigenetic changes driving tumor evolution during treatment, providing insights for treatment resistance. Immunotherapies have been successful in other solid malignancies but have had limited success in GBM due to several resistance mechanisms leading to a pro-tumoral microenvironment. Anti-angiogenic therapies show modest benefits but ultimately lead to treatment resistance through the adaptation of tumor cells. This Special Issue aims to address the advances in our understanding of how the biology of GBM tumor cells and the interactions between these tumors cells and the tumor microenvironment drive therapeutic resistance. We will also describe possible approaches to overcoming this resistance in order to improve patient outcomes.

Guest Editors

Dr. Manish K. Aghi

Department of Neurological Surgery, University of California, San Francisco, CA 94143, USA

Dr. Saket Jain

Department of Neurological Surgery, University of California, San Francisco, CA 94143, USA

Deadline for manuscript submissions

closed (31 October 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/107156

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)